KSQ-4279 is under clinical development by KSQ Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KSQ-4279’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KSQ-4279 overview

KSQ-4279 is under development for the treatment of ovarian cancer, colorectal and triple negative breast cancer and metastatic solid tumors. The drug candidate is developed based on CRISPRomics technology. It is personalized therapy. It is a first-in-class USP1 inhibitor. it acts by inhibiting deubiquitinating activity of Ubiquitin carboxyl-terminal hydrolase-1 (USP1).

KSQ Therapeutics overview

KSQ Therapeutics is a drug development company that focuses on the development of novel therapeutics for the treatment of oncology. It treats wide range of cancers, in solid tumors, as well as autoimmune diseases. KSQ Therapeutics serves product under the brand CRISPRomics. The company utilizes CRISPRomics, a functional genomics engine that utilizes a suite of proprietary CRISPR/Cas9 tools to enable high confidence drug development. Its eTILs carters in revolutionizing the treatment of solid tumors. KSQ Therapeutics is headquartered in Lexington, Massachusetts, the US.

For a complete picture of KSQ-4279’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.